Endgame

In May 2026, Endgame’s category mix was concentrated in Vapor Pens at 51.29% share with a year-over-year decline of 32.55% and a month-over-month dip of 1.68%, while Concentrates held 45.10% share with a year-over-year decline of 20.94% but a month-over-month increase of 9.35%. Smaller lines contracted sharply, with Pre-Roll at 2.81% share down 77.51% year-over-year and 5.46% month-over-month, and Flower at 0.80% share down 94.44% year-over-year and 27.42% month-over-month; paired with a 12.50% year-over-year drop in average price to $27.85, the mix indicates reliance on two inhalable formats while de-emphasizing traditional combustion. Given Endgame’s Vapor Pens rank of 13 in Saskatchewan and a 37.46% brand-level year-over-year sales decline, the pattern implies category concentration risk where slight Vapor Pens volatility can outweigh Concentrates gains, making mix diversification more material than incremental pricing moves.

The shift toward Concentrates stability month-over-month (+9.35%) alongside Vapor Pens slippage (−1.68%) suggests Endgame’s positioning is tilting toward value-seeking inhalable shoppers as average prices in Vapor Pens at $30.61 and Concentrates at $25.83 converge with a 12.50% brand-wide price reduction. With Vapor Pens still contributing over half of sales at 51.29% but underperforming year-over-year versus Concentrates (−32.55% vs −20.94%), and with peripheral categories shrinking rapidly (Pre-Roll −77.51% YoY, Flower −94.44% YoY), the implication is that Endgame’s defensible lane in May 2026 lies in doubling down on high-repeat formats while rebuilding an entry-price ladder inside core inhalables rather than reviving subscale segments.